Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination

Zachary Kincaid, Sekhu Ansari, Joshua Schwieterman, Mary Antonysamy, Dwaipayan Patnaik, Shane O'Brien, Michael McCabe, Mohammad Azam

Blood (2025) 146 (Supplement 1): 7850.

https://doi.org/10.1182/blood-2025-7850

Published: 2025

Journal Articles

Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML

Meenu Kesarwani, Mohammad Azhar, Zachary Kincaid, Sekhu Ansari, Joshua Schwieterman, Mohammad Azam

Blood (2025) 146 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2025-1514

Published: 2025

Journal Articles

Novel BCR::ABL1 fusion alongside T315I reveals mechanism for dual ponatinib/asciminib resistance and proves sensitive to addition of axitinib

Valentina Nardi, Mohammad Azam, Joshua Schwieterman, Sekhu Ansari, Meenu Kesarwani, George Daley, Zachary Kincaid

Blood (2025) 146 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2025-1501

Published: 2025

Journal Articles

Selective degradation of oncogenic signaling nodes by momelotinib-based protacs exerts potent anti-leukemic response in B-ALL, AML, and MF while sparing normal cells

Joshua Schwieterman, Sekhu Ansari, Mohammad Azam

Blood (2025) 146 (Supplement 1): 6108.

https://doi.org/10.1182/blood-2025-6108

Published: 2025

Journal Articles

Momelotinib-mediated transcriptional reprogramming induces synthetic lethal interaction with calcineurin-NFAT signaling

Sekhu Ansari, Meenu Kesarwani, Zachary Kincaid, Mohammad Azhar, Joshua Schwieterman, Mohammad Azam

Blood (2025) 146 (Supplement 1): 756.

https://doi.org/10.1182/blood-2025-756

Published: 2025

Journal Articles

A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy

Valentina Nardi, Joshua Schwieterman, Zachary Kincaid, Andrew M. Brunner, Maria Reyes, Gabriel K. Griffin, Sekhu Ansari, Mohammad Azam

Blood (2024) 144 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2024-211279

Published: 2024

Journal Articles

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

Zachary Kincaid, Sekhu Ansari, Mohammad Azhar, Meenu Kesarwani, Mohammad Azam

Blood (2024) 144 (Supplement 1): 5814.

https://doi.org/10.1182/blood-2024-211412

Published: 2024

Journal Articles

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

Meenu Kesarwani, Zachary Kincaid, Mohammad Azhar, Mohammad Azam

Blood (2024) 144 (Supplement 1): 5786.

https://doi.org/10.1182/blood-2024-211448

Published: 2024

Journal Articles

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Meenu Kesarwani, Mohammad Azhar, Sekhu Ansari, Zachary Kincaid, Mohammad Azam

Blood (2023) 142 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2023-189845

Published: 2023

Journal Articles

Rational Polypharmacological Targeting of FLT3, JAK2, ABL and ERK1 By Pluripotin Suppresses the Adaptive Resistance to FLT3 Inhibitors in AML

Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Tahir Latif, Sekhu Ansari, William Seibel, Mohammad Azam

Blood (2022) 140 (Supplement 1): 3101–3102.

https://doi.org/10.1182/blood-2022-167484

Published: 2022

Journal Articles

Targeting the Negative-Feedback Inhibitor of MAPK Signaling Selectively Eliminates Leukemic Clone in Cnl/Acml

Meenu Kesarwani, Mohammad Azhar, Zachary Kincaid, Mohammad Azam

Blood (2022) 140 (Supplement 1): 9582–9583.

https://doi.org/10.1182/blood-2022-167291

Published: 2022

Journal Articles

PLaCatinG AML1-ETO

Mohammad Azam

Blood (2022) 139 (7): 959–961.

https://doi.org/10.1182/blood.2021014416

Published: 2022

Journal Articles

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML

Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Mark Wunderlich, Tahir Latif, Daniel Starczynowski, Mohammad Azam

Blood (2021) 138 (Supplement 1): 206.

https://doi.org/10.1182/blood-2021-148822

Published: 2021

Journal Articles

DUSP1 Confers Oncogene Dependence in CSF3R Induced Leukemia

Meenu Kesarwani, Zachary Kincaid, BS, Mohammad Azam, PhD

Blood (2018) 132 (Supplement 1): 1341.

https://doi.org/10.1182/blood-2018-99-119092

Published: 2018

Journal Articles

Loss of DUSP1 Is Synthetic Lethal to JAK2 V617F

Meenu Kesarwani, Zachary Kincaid, BS, Tahir Latif, MD, Mohammad Azam, PhD

Blood (2018) 132 (Supplement 1): 51.

https://doi.org/10.1182/blood-2018-99-115503

Published: 2018

Journal Articles

A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML

Meenu Kesarwani, PhD, Zachary Kincaid, BS, Ahmed Ramadan Gomma, PhD, Erika Huber, Sara Rohrabaugh, PhD, H. Leighton Grimes, PhD, Mohammad Azam, PhD

Blood (2016) 128 (22): 3056.

https://doi.org/10.1182/blood.V128.22.3056.3056

Published: 2016

Journal Articles

Enhanced MAPK Signaling Constitute Non-Oncogene Addiction in CSF3R Induced Leukemia

Sara Rohrabaugh, PhD, Meenu Kesarwani, PhD, Zachary Kincaid, BS, Erika Huber, H. Leighton Grimes, PhD, Mohammad Azam, PhD

Blood (2016) 128 (22): 632.

https://doi.org/10.1182/blood.V128.22.632.632

Published: 2016

Journal Articles

Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling

Kiersten Ricci, MD, Erika Huber, Ashok Raj, MD, Mohammad Azam, PhD, Theodosia A. Kalfa, MD PhD

Blood (2016) 128 (22): 3137.

https://doi.org/10.1182/blood.V128.22.3137.3137

Published: 2016

Journal Articles

Overcoming Drug Resistance Of FLT3-ITD By SAR302503

Meenu Kesarwani, PhD, Erika Huber, BS, Mohammad Azam, PhD

Blood (2013) 122 (21): 5023.

https://doi.org/10.1182/blood.V122.21.5023.5023

Published: 2013

Journal Articles

Targeting the Genetic Resistance of JAK2 and BCR/ABL by TG101348

Meenu Kesarwani, PhD, Mohammad Azam, PhD

Blood (2012) 120 (21): 3765.

https://doi.org/10.1182/blood.V120.21.3765.3765

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination

Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML

Novel BCR::ABL1 fusion alongside T315I reveals mechanism for dual ponatinib/asciminib resistance and proves sensitive to addition of axitinib

Selective degradation of oncogenic signaling nodes by momelotinib-based protacs exerts potent anti-leukemic response in B-ALL, AML, and MF while sparing normal cells

Momelotinib-mediated transcriptional reprogramming induces synthetic lethal interaction with calcineurin-NFAT signaling

A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Rational Polypharmacological Targeting of FLT3, JAK2, ABL and ERK1 By Pluripotin Suppresses the Adaptive Resistance to FLT3 Inhibitors in AML

Targeting the Negative-Feedback Inhibitor of MAPK Signaling Selectively Eliminates Leukemic Clone in Cnl/Acml

PLaCatinG AML1-ETO

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML

DUSP1 Confers Oncogene Dependence in CSF3R Induced Leukemia

Loss of DUSP1 Is Synthetic Lethal to JAK2 V617F

A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML

Enhanced MAPK Signaling Constitute Non-Oncogene Addiction in CSF3R Induced Leukemia

Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling

Overcoming Drug Resistance Of FLT3-ITD By SAR302503

Targeting the Genetic Resistance of JAK2 and BCR/ABL by TG101348

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only